Primarily biliary cirrhosis, gallstones or gallbladder disorders, or hypoalbuminaemic states as nephritic syndrome. Severe hepatic impairment. Renal impairment.
May enhance the effects of oral anticoagulants. Potential risk of warfarin displacement from protein-binding sites. Altered glucose tolerance in diabetic & non-concomitant fenofibrate therapy w/ tolbutamide, other sulfonylurea antidiabetics. Phenytoin & furosemide (in patients w/ hypoalbuminemia).
Sign Out
